Why chemicals and pharma distorted Swiss foreign trade in August
The decline in goods exports in August says less about the breadth of the Swiss export economy than the headline suggests.
Swiss goods exports fell by 17.2 percent in August 2026 compared with the previous month, adjusted for seasonal effects. That figure looks like a setback for the export economy. A look at the detailed data from the Federal Office for Customs and Border Security (FOCBS) changes the reading, however: only chemical and pharmaceutical products pulled the overall result down. Without that segment, export development was positive overall.
A monthly figure with a big lever
The countermovement is so pronounced also because July had brought an exceptionally strong gain: back then, exports rose by 14.6 percent in seasonally adjusted terms. Already in its July release, the FOCBS had pointed out that chemicals and pharmaceuticals decisively shaped the result. The August decline is therefore not solid evidence that the entire export base gave way at the same time.
This distinction is central to how the monthly figures should be read. Foreign trade statistics report values, not the quantity of goods exported. When delivery dates and invoice values shift for a few high-priced medicines, active substances or chemical products, the national figure can change sharply. That does not automatically allow conclusions about production, order books or demand in all other industries.
Why chemicals and pharmaceuticals shape the statistics so strongly
Chemicals and pharmaceuticals hold an exceptionally large position in Swiss exports. According to the FOCBS, chemical and pharmaceutical products accounted for 52.7 percent of all goods exports in 2024. That weight explains why this segment moves the monthly overall series disproportionately.
This is not economically trivial: the sector creates value added, jobs and export revenues. For short-term monitoring of the economy, however, the concentration is a limitation. Anyone looking only at the total value quickly mistakes a single industry's movement for broad-based weakness in the economy. That is why the FOCBS explicitly separates its commentary by goods category and points to the trend excluding chemicals and pharmaceuticals.
Imports also declined
On the import side, goods trade fell by 11.6 percent in August. Here too, the FOCBS names chemical and pharmaceutical products as the main cause. Exports and imports thus both declined in the same month, yet Switzerland still recorded a trade surplus of 5.6 billion francs.
That surplus does not mean that all parts of the foreign economy are performing equally well. It merely shows that the value of the goods exported exceeded the value of the goods imported in the reporting month. For companies outside chemicals and pharmaceuticals, exchange rates, the development of key sales markets, energy and input costs, and demand for capital goods remain decisive. These factors cannot be read from a single monthly figure alone.
How to read monthly data correctly
Foreign trade statistics are indispensable for watching the current economy, but they are not a balance sheet of individual companies. They capture cross-border trade in goods. Services, which are likewise important for Switzerland, do not appear in them. Nor does the monthly figure answer whether a shift in a single product reverses in the following month.
That is why seasonally adjusted series and comparisons across several months are more informative than a single percentage swing. The FOCBS uses seasonal adjustment to make recurring patterns over the course of the year more comparable. The adjustment does not, however, remove the particular effect of goods categories with very high trade values.
What the figure says about the economy – and what it does not
The August data are a warning against hasty conclusions, not automatically a warning signal for the entire Swiss economy. The positive development of exports excluding chemicals and pharmaceuticals argues against a broad-based weakening in goods trade. At the same time, it would be just as wrong to simply ignore the overall decline: the pharmaceutical industry is so weighty for Switzerland that its swings can genuinely influence foreign trade, individual regions and supply chains.
What matters, therefore, is the development over several months and quarters. The FOCBS publishes foreign trade statistics monthly and provides the results by goods, countries and direction of traffic. For the next assessment, it will be necessary to check whether the August decline remains primarily a countermovement after the strong July, or whether the weakening shows up in further areas.
